Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HRMY
stocks logo

HRMY

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
204.52M
+18.35%
--
--
218.24M
+17.31%
--
--
235.86M
+17.19%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Harmony Biosciences Holdings, Inc. (HRMY) for FY2025, with the revenue forecasts being adjusted by 0.1% over the past three months. During the same period, the stock price has changed by 27.82%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.1%
In Past 3 Month
Stock Price
Go Up
up Image
+27.82%
In Past 3 Month
6 Analyst Rating
up Image0
Wall Street analysts forecast HRMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRMY is 51.17 USD with a low forecast of 31.00 USD and a high forecast of 70.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
1 Sell
Moderate Buy
up Image0
Current: 36.430
sliders
Low
31.00
Averages
51.17
High
70.00
up Image0
Current: 36.430
sliders
Low
31.00
Averages
51.17
High
70.00
Goldman Sachs
Corinne Johnson
Neutral
maintain
$33
2025-07-10
Reason
Goldman Sachs
Corinne Johnson
Price Target
$33
2025-07-10
maintain
Neutral
Reason
Goldman Sachs analyst Corinne Johnson resumed coverage of Harmony Biosciences with a Neutral rating and $33 price target. The firm expects the outlook for the Wakix franchise to remain the driver of the shares.
Deutsche Bank
Buy
maintain
$54 -> $55
2025-07-10
Reason
Deutsche Bank
Price Target
$54 -> $55
2025-07-10
maintain
Buy
Reason
Deutsche Bank raised the firm's price target on Harmony Biosciences to $55 from $54 and keeps a Buy rating on the shares. The firm says the company has a key clinical catalyst this quarter with readout of the Phase 3 RECONNECT trial in Fragile X syndrome. The data could materially drive shares if positive and "presents asymmetric risk-reward to the upside," the analyst tells investors in a research note.
Oppenheimer
Oppenheimer
Outperform
initiated
$61
2025-06-02
Reason
Oppenheimer
Oppenheimer
Price Target
$61
2025-06-02
initiated
Outperform
Reason
Oppenheimer assumed coverage of Harmony Biosciences with an Outperform rating and $61 price target. The firm notes Harmony BioSciences' solid Q1 results featured $184.7M in revenues, beating both our/consensus $178.5M/$182.3M estimates. Despite typical Q1 seasonal dynamics, Oppenheimer is encouraged by WAKIX's ongoing momentum with average number of patients growing to about 7,200, and continuing adoption among prescribers. Management expects continued patient growth through the year to support its reiterated FY25 revenue guidance of $820M-$860M. The firm is also encouraged by progress in the Pitolisant-HD and Pitolisant-GR programs. In terms of the pipeline, while not currently included in its valuation, Oppenheimer sees attractive upside potential in Harmony's neurobehavioral and epilepsy pipelines. Phase 3 FXS top-line results remain on track for Q3 2025.
Mizuho
Outperform
maintain
$44 -> $48
2025-05-15
Reason
Mizuho
Price Target
$44 -> $48
2025-05-15
maintain
Outperform
Reason
Needham
Ami Fadia
Strong Buy
Reiterates
$50
2025-04-10
Reason
Needham
Ami Fadia
Price Target
$50
2025-04-10
Reiterates
Strong Buy
Reason
Needham
Ami Fadia
Strong Buy
Reiterates
$50
2025-04-08
Reason
Needham
Ami Fadia
Price Target
$50
2025-04-08
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Harmony Biosciences Holdings Inc (HRMY.O) is 11.17, compared to its 5-year average forward P/E of 23.77. For a more detailed relative valuation and DCF analysis to assess Harmony Biosciences Holdings Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
23.77
Current PE
11.17
Overvalued PE
47.18
Undervalued PE
0.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
12.44
Current EV/EBITDA
5.87
Overvalued EV/EBITDA
20.54
Undervalued EV/EBITDA
4.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
4.54
Current PS
2.31
Overvalued PS
6.74
Undervalued PS
2.34

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 18208.08% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

HRMY News & Events

Events Timeline

(ET)
2025-06-11
08:13:20
Harmony Biosciences presents preclinical data for BP1.15205
select
2025-06-05 (ET)
2025-06-05
09:20:55
Harmony Biosciences settles generic drug litigation, strengthens patent
select
2025-05-06 (ET)
2025-05-06
07:56:22
Harmony Biosciences backs FY25 revenue view $820M-$860M, consensus $840.4M
select
Sign Up For More Events
Sign Up For More Events

News

Preview
3.0
05:00 AMNASDAQ.COM
Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again

  • Earnings Performance: Harmony Biosciences Holdings, Inc. has consistently beaten earnings estimates, with an average surprise of 23.53% over the last two quarters, and a positive Earnings ESP of +19.75%, indicating strong potential for future earnings beats.

  • Investment Insights: The combination of a positive Earnings ESP and a Zacks Rank #2 (Buy) suggests that investors may benefit from considering HRMY as a stock with promising earnings prospects, while also emphasizing the importance of checking Earnings ESP ahead of quarterly releases.

Preview
6.5
07-16NASDAQ.COM
3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY)

  • Growth Stock Investment: Investors are focusing on growth stocks like Harmony Biosciences Holdings, Inc. (HRMY), which show strong earnings and cash flow growth, making them attractive for potential high returns despite inherent risks.

  • Zacks Growth Score: Harmony Biosciences has a favorable Growth Score of B and a Zacks Rank of #2, indicating positive earnings estimate revisions and suggesting it could outperform the market as a solid choice for growth investors.

Preview
1.0
07-15Newsfilter
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

  • Event Announcement: Harmony Biosciences will participate in the virtual H.C. Wainwright "HCW@Home" series on July 17, 2025, at 10:00 a.m. ET, with a webcast available on their investor page.

  • Company Overview: Harmony Biosciences focuses on developing therapies for rare neurological diseases, emphasizing innovation and empathy to address unmet medical needs since its establishment in 2017.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Harmony Biosciences Holdings Inc (HRMY) stock price today?

The current price of HRMY is 36.43 USD — it has increased 3.46 % in the last trading day.

arrow icon

What is Harmony Biosciences Holdings Inc (HRMY)'s business?

Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

arrow icon

What is the price predicton of HRMY Stock?

Wall Street analysts forecast HRMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRMY is 51.17 USD with a low forecast of 31.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Harmony Biosciences Holdings Inc (HRMY)'s revenue for the last quarter?

Harmony Biosciences Holdings Inc revenue for the last quarter amounts to 184.73M USD, increased 19.48 % YoY.

arrow icon

What is Harmony Biosciences Holdings Inc (HRMY)'s earnings per share (EPS) for the last quarter?

Harmony Biosciences Holdings Inc. EPS for the last quarter amounts to 0.78 USD, increased 16.42 % YoY.

arrow icon

What changes have occurred in the market's expectations for Harmony Biosciences Holdings Inc (HRMY)'s fundamentals?

The market is revising Upward the revenue expectations for Harmony Biosciences Holdings, Inc. (HRMY) for FY2025, with the revenue forecasts being adjusted by 0.1% over the past three months. During the same period, the stock price has changed by 27.82%.
arrow icon

How many employees does Harmony Biosciences Holdings Inc (HRMY). have?

Harmony Biosciences Holdings Inc (HRMY) has 246 emplpoyees as of July 18 2025.

arrow icon

What is Harmony Biosciences Holdings Inc (HRMY) market cap?

Today HRMY has the market capitalization of 2.09B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free